Importantly, the combination of ICI and CNI, a drug that causes T cell dysfunction by reducing T cell activation through lowering the translocation of nuclear factor of activated T cells (NFAT) into the nucleus, interleukin 2 (IL-2) production and IL-2 receptor expression15, widely used for graft maintenance, has been associated with reduced anti-tumor response. The gene discussed is IL2; the disease is neoplasm.